Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue 6, 2014, Pages 465-469

  Sahin, Serap B ^a   Ayaz, Teslime ^a   Cure, Medine C ^a   Sezgin, Hacer ^a   Ural, Ulku M ^a   Balik, Gulsah ^a   Sahin, Figen K ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

Dehydroepiandrosterone sulfate; Fibroblast Growth Factor 21; High sensitive C reactive protein; HOMA IR; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; METABOLISM; YOUNG ADULT;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84902783821     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2014.900821     Document Type: Article

References (25)

1. Azziz R, Woods KS, Reyna R, Key T J, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
3. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095-105.
4. Wild RA. Long-term health consequences of PCOS. H um Reprod Update 2002; 8: 231-41.
5. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-12.
6. Kharitonenkov A, Dunbar J D, Bina H A, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, Hale JE, Coskun T, Shanafelt AB. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 2008; 215: 1-7.
7. Badman MK, Pissios P, Kennedy A R, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-37.
8. Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA, Cuevas-Ramos G, Cuevas-Sosa AA, Gomez-Perez FJ. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev 2009; 5: 216-20.
9. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-25.
10. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. Clin Invest 2005; 115: 1627-35.
11. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-81.
12. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Vé niant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-9.
13. Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J, Rissanen A, Suomalainen A, Pietiläinen KH. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011; 96: 351-5.
14. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-53.
15. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-63.
16. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71: 369-75.
17. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 65-8.
18. Semba R D, Sun K, Egan J M, Crasto C, Carlson O D, Ferrucci L. Relationship of serum fibroblast growth factor with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012; 97: 1375-82.
19. Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-47.
20. Matthews DR, Hosker JP, Rudenski A S, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
21. Gokcel A, Ozsahin AK, Sezgin N, Karakose H, Ertorer M E, Akbaba M, Baklaci N, Sengul A, Guvener N. High prevalence of diabetes in Adana, asouthern province of Turkey. Diabetes Care 2003; 26: 3031-34.
22. Gäl man C, Lundås en T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169-74.
23. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. Clin Endocrinol Metab 2009; 94: 2151-6.
24. Gorar S, Culha C, Uc ZA, Dellal FD, Serter R, Aral S, Aral Y. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 819-26.
25. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010; 5: e15534.